SP
Sprint Bioscience AB
SPRINT.ST · STO
3.65 kr +0.27% (+0.01 kr)
1M +33.21%
Market Cap 385.1M kr
P/E Ratio 5.09x
Div. Yield -
ROE 94.09%
Bulios Fair Price
3.89 kr
6.6% upside
Current Price
3.65 kr
Undervalued Fair Value Overvalued
According to Bulios Fair Price, SPRINT.ST is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Moderate
4/9Valuation
90 /100
Cheap P/E 5.09x
EV/EBITDA 3.69x
P/S 2.77x
Growth
100 /100
Growing Rev. growth 1,162.87%
Book val. growth 61.70%
EPS growth N/A
Profitability
100 /100
Strong Gross margin 78.03%
Net margin 54.37%
Op. margin 56.21%
Quality
100 /100
Excellent ROIC 86.82%
ROE 94.09%
ROA 72.55%
Debt
100 /100
Low Debt/Equity 0.00x
Current ratio 7.09x
Int. coverage 16.74x
Stability
16 /100
Unstable Beta -0.52x
Rev. volatility 35,006.51%
EPS volatility 2,499.78%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about SPRINT.ST
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Johan Emilsson
Employees
32
Headquarters
Huddinge
Upcoming events
11 NOV
Earnings
Upcoming earnings report